Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLI1 | P08151 | 1/20 | 0.58 |
| ▸ | SCN4A | P35499 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 6/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832254 | 1.00 | GLI1 (0.58) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL16992331 | 1.00 | GLI1 (0.58) | GLI1SCN4ANOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL5430649 | 0.98 | GLI1 (0.56) | GLI1SCN4ANOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL1191047 | 0.98 | GLI1 (0.56) | GLI1SCN4ANOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL4590185 | 0.98 | GLI1 (0.56) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL255493 | 0.94 | GLI1 (0.66) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL490079 | 0.94 | GLI1 (0.66) | GLI1SCN4ANOS2NOS3NOS1 | |
| SCHEMBL894617 | 0.94 | GLI1 (0.66) | GLI1SCN4ANOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL6387850 | 0.92 | GLI1 (0.63) | GLI1SCN4ANOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL490043 | 0.92 | GLI1 (0.63) | GLI1SCN4ANOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013755-B1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2025-01-08 | — | — | EP | claimed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | claimed |
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | claimed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | claimed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | claimed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | claimed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | claimed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | claimed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | claimed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | claimed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-111601799-B | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | disclosed |
| US-20220144759-A1 | COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| EP-1296976-B1 | NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI AVENTIS (FR) | 2005-01-26 | — | — | EP | disclosed |
| EP-1296976-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sanofi-Aventis (FR) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001098295-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2001-12-27 | — | — | WO | disclosed |
| US-6331537-B1 | TREATING NEUROLOGICAL DISORDERS IN ANIMALS | GPI NIL HOLDINGS, INC. | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | GLI1 1146/4885SCN4A 3158/4885NOS2 60/4885 |
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | GLI1 2064/4885SCN4A 1387/4885NOS2 1276/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | GLI1 690/4885SCN4A 2425/4885NOS2 89/4885 |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | GLI1 1857/4885SCN4A 1725/4885NOS2 1105/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | GLI1 60/4885SCN4A 3634/4885NOS2 3187/4885 |
| US-20220144759-A1 | COMPOUND | SFXN3, SFXN1, CBR3 | GLI1 2002/4885SCN4A 1279/4885NOS2 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.